The Singer Group applies aging-related principles to study patient-centered outcomes in advanced lung disease and lung transplant along three themes:
1) Improving transplant candidate risk stratification by investigating frailty and body composition;
2) Patient centered outcomes, including functioning, disability, health-related quality of life (HRQL), and survival; and
3) Developing novel instruments for use in advanced lung disease and lung transplantation.
Broadly, our goal is to understand how lung transplant does or does not help patients get back to doing the things in life that they find meaningful. We accomplish this through single-center and multicenter collaborations. To support these broad efforts, Dr. Singer founded and now co-directs the UCSF Advanced Lung Disease and Transplant research program, a cross-departmental research cooperative that includes clinical, translational, and basic science investigators.
In addition, our group leads industry sponsored clinical trials of novel therapeutics for adults living with cystic fibrosis as well as bronchiectasis.